MedTrace Logo

The Forteo Alendronate Comparator Trial

NCT02416271 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2015-04-14

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.

Conditions

Interventions

DRUG

Teriparatide

Administered SC

DRUG

Alendronate

Administered orally

DIETARY_SUPPLEMENT

Calcium

Administered orally

DIETARY_SUPPLEMENT

Vitamin D

Administered orally

DRUG

Placebo-Oral

Administered orally

DRUG

Placebo-SC

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2003-05-31
Completion
2003-05-31

Countries

  • United States
  • Brazil
  • Mexico
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02416271 on ClinicalTrials.gov